Shopping Cart
Remove All
Your shopping cart is currently empty
Toripalimab
Catalog No. T77117 Copy Product Info
Purity: 95%
🥰Excellent
Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma.
Toripalimab
Copy Product Info🥰Excellent
Catalog No. T77117
Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma.
Toripalimab
Cas No. 1924598-82-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $81 | - | In Stock | |
| 5 mg | $207 | - | In Stock | |
| 10 mg | $330 | - | In Stock | |
| 25 mg | $660 | - | In Stock | |
| 50 mg | $1,060 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.2% (SDS-PAGE); 96.8% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma. |
| In vivo | Methods: Toripalimab (0.3-10 mg/kg, intraperitoneal injection, twice a week, 6 times) was used to treat transgenic mice with human PD-1 knockout, and its therapeutic effect on tumors in mice was observed. Results: In the 1, 3, and 10 mg/kg treatment groups, tumor growth inhibition was observed in a dose-dependent manner, demonstrating significant anti-tumor efficacy. [1] |
| Reactivity | Human |
| Verified Activity | Immobilized Human PD-1 Protein (His) (TMPY-00897) at 1 μg/mL (100 μL/well) can bind Toripalimab. The EC50 is 6.96 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | PDCD1/PD-1/CD279 |
| Molecular Weight | 147.29 kDa |
| Cas No. | 1924598-82-2 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Toripalimab | purchase Toripalimab | Toripalimab cost | order Toripalimab | Toripalimab in vivo | Toripalimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.